Suven Life Sciences, a biopharmaceutical company, has received four product patents for its new chemical entities (NCEs).
These patents represent the NCEs for the treatment of disorders associated with neurodegenerative diseases.
The four product patents, two from China, one from Mexico and one from New Zealand, are valid through 2028.
The patents cover the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
Suven CEO Venkat Jasti said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
